Nagar SP, Fan Y, Meyers J, Tighe RM. Real-world treatment patterns of nintedanib among patients with idiopathic pulmonary fibrosis in the United States. Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10-a):S71.
Nagar S, Patel J, Stanford RH. Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: a U.S. database study. Manag Care. 2018 May;27(5):40-7.
Dave I, Nagar SP, Arif AA, Laditka SB, Huber LR. Association between prescription-taking status and total direct health care cost among patients with asthma. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A357.
Basu A, Dalal A, Canonica GW, Forshag M, Yancey SW, Nagar S, Bell CF. Economic analysis of the Phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):121-31. doi: 10.1080/14737167.2017.1298444
Mytelka DS, Lorenzo M, Stafkey-Mailey D, D’yachkova Y, Nagar S, Candrilli SD, Kaye JA. Advanced soft tissue sarcoma: systemic treatment patterns and survival in Germany. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A760.
Stanford RH, Nagar S, Lin X, O'Connor RD. Use of ICS/LABA on asthma exacerbation risk in patients within a medical group. J Manag Care Pharm. 2015 Nov;21(11):1014-9.
Dalal AA, Patel JP, D'Souza A, Farrelly E, Nagar S, Shah M. Impact of COPD exacerbation frequency on costs for a managed care population. J Manag Care Pharm. 2015 Jul;21(7):575-83.
Diette GB, Dalal AA, D'Souza AO, Lunacsek O, Nagar SP. Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States. Int J Chron Obstruct Pulmon Dis. 2015 Feb 24;10:415-22.
Patel JG, Nagar SP, Dalal AA. Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States. Int J Chron Obstruct Pulmon Dis. 2014 Mar;19(9):289-300.
Stanford RS, Nagar SP, Lin X, O'Conner R. Impact of change in inhaled corticosteroids/long-acting beta agonist combination (ICS/LABA) use on the risk of asthma exacerbations in asthma patients within a medical group. Poster presented at the 2014 AAAAI Annual Meeting; February 2014. San Diego, CA. [abstract] J Allergy Clin Immunol. 2014 Feb; 133(2):AB7.
Dalal AA, Shaw MB, D'Souza AO, Lunacsek OE, Nagar SP, Crater GD. Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD. Resp Res. 2012 May;31(13):41.